NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

NCT05529940 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

609

Enrollment

OTHER

Sponsor class

Conditions

Resectable Pancreatic Cancer
Neoadjuvant Chemotherapy
Effects of Chemotherapy

Interventions

DRUG: Folfirinox

Sponsor

Seoul National University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]